(Q38285827)

1 September 2017

1 reference

title

Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy (English)

1 reference

1 September 2017

0 references

1 reference

1 reference

1 reference

Soken-Nakazawa J Song

series ordinal

1

1 reference

1 September 2017

Kazuyuki Yoshizaki

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

10 December 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

1 September 2017

published in

1 reference

1 September 2017

volume

11

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

307-316

1 reference

New therapies for treatment of rheumatoid arthritis

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Rheumatoid arthritis. Pathophysiology and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

The role of TNF alpha and IL-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Interleukin-6 induces hepcidin expression through STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Humanized antihuman IL-6 receptor antibody, tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

IL-6 in inflammation, immunity, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Clinical safety of tocilizumab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Tocilizumab versus adalimumab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome-Wide DNA Microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.992779

10.1517/17425255.2015.992779

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference